5 results about "Panaxatriol" patented technology

This invention discloses a compound preparation for treating vascular dementia and its preparation method. The active pharmaceutical ingredient consists of protopanaxadiol and gallic acid in a 1:1 mass ratio, and the dosage form is liposomes. The preparation method includes extraction, mixing, liposome preparation, and optional freeze-drying steps: protopanaxadiol and gallic acid are extracted and purified from ginseng rhizome and Terminalia chebula fruit, respectively. After mixing, they are combined with phospholipids and cholesterol to prepare a lipid membrane. The membrane is then homogenized by hydration, low-temperature ultrasound, and high-pressure microfluidic jet to obtain a homogeneous liposome suspension, which can be further freeze-dried into a freeze-dried powder. The 1:1 composition of protopanaxadiol and gallic acid targets multiple points on the pathological mechanism of vascular dementia, showing significant therapeutic effects and broad application prospects. This preparation uses a liposome dosage form to improve the bioavailability of the active ingredient, the preparation process parameters are controllable, the active ingredient has high purity, the liposomes have uniform particle size, high encapsulation efficiency, and good stability.

The invention is suitable for the technical field of biological medicine, and provides application of 20 (S)-protopanaxatriol in preparation of a medicine for inhibiting tumor metastasis of liver cancer chemotherapy. According to the embodiment of the invention, a molecular mechanism of chemotherapy-induced liver cancer immunosuppression and metastasis increase is analyzed and studied, a key effect of an SHP2-PI3K / AKT signal axis in TAM M2 polarization is disclosed, a novel natural small molecule 20 (S)-protopanaxatriol capable of inhibiting the activity of SHP2 is provided, TAM is blocked from being polarized to an M2 type by inhibiting phosphorylation of SHP2 and activation of a downstream PI3K / AKT signal channel, and the activity of SHP2 is inhibited. Therefore, the tumor immune microenvironment after chemotherapy is improved, the tumor metastasis risk after chemotherapy is reduced, and the overall treatment effect is improved on the premise that safety is guaranteed.

The invention discloses a novel oil-soluble micelle preparation. The component A comprises lecithin, soya bean lecithin, egg yolk lecithin, 1-palmitoyl-2-oleoyl lecithin, phosphatidylserine, phosphatidylinositol, phosphatidyl glycerol, cardiolipin, cephalin and dipalmitoyl phosphatidylcholine, and the component B comprises lecithin, soya bean lecithin, egg yolk lecithin, 1-palmitoyl-2-oleoyl lecithin, phosphatidylserine, phosphatidylinositol, phosphatidyl glycerol, phosphatidylcholine, cephalin and dipalmitoyl phosphatidylcholine; one or more of dipalmitoyl phosphatidyl ethanolamine and dipalmitoyl phosphatidyl ethanolamine; the component B comprises a component B1 and a component B2, and the component B1 comprises one or more of phytosterol, cholesterol, ergosterol, protopanoxadiol, protopanaxatriol, ganoderic acid, phytol, isophytol, retinol, andrographolide, paclitaxel, artemisinin and bisabolol; and the component B2 is prepared from one or more of 1, 2-hexanediol, ethylhexylglycerin, cyclohexyl glycerin, absolute ethyl alcohol and isosorbide dimethyl ether. The key point of the invention is to provide a low-cost formula and a low-cost preparation method for preparing the oil-soluble micelle preparation.

The present application belongs to the technical field of medicine and pharmacy, and in particular relates to an application of proto-prosolan in preparation of a Streptococcus suis type 2 capsule inhibitor. The present application discloses that proto-prosolan can significantly weaken the pathogenicity and immune escape ability of Streptococcus suis type 2 by inhibiting capsule synthesis, and then effectively plays an anti-infection role. Compared with vaccines, antibodies and phage enzymes and other highly limited anti-capsule strategies specific to serotypes, proto-prosolan, as an anti-toxicity inhibitor of Streptococcus suis type 2, has potential advantages such as broad spectrum, and has important scientific significance and application value for the research and development of new anti-drugs in the future. The proto-prosolan can be applied to the preparation of a Streptococcus suis type 2 capsule inhibitor and a drug for preventing and treating Streptococcus suis type 2 infection.

This invention belongs to the field of biotechnology, specifically relating to the preparation, conversion, and application of a ginsenoside probiotic composition. By adding probiotics capable of degrading ginsenosides to ginseng products, this invention enhances the bioavailability of ginsenosides in the human body by degrading ginsenosides into ginsenoside diol and ginsenoside triol. The core aglycone of this probiotic composition achieves a conversion rate exceeding 80% within one hour, providing better and more convenient treatment options in anti-inflammatory, immune-regulating, and other related fields, thereby increasing therapeutic efficacy.